Wed, 11 Nov 2026 16:32:00 -0500 · 1 day ago Addex Spin-out Neurosterix Closes $105 Million Series B Financing
Thu, 29 Oct 2026 02:00:00 -0400 · 14 days ago ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
2026-10-08T09:20:27.000Z · 5 weeks ago Addex Therapeutics spin-out company completes NTX-253 clinical studies
Thu, 08 Oct 2026 01:00:00 -0400 · 5 weeks ago Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Fri, 02 Oct 2026 01:00:00 -0400 · 5 weeks ago Addex Therapeutics Announces Executive Management Changes
Mon, 28 Sep 2026 01:00:00 -0400 · 6 weeks ago Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Fri, 25 Sep 2026 01:00:00 -0400 · 6 weeks ago Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Thu, 24 Sep 2026 01:00:00 -0400 · 7 weeks ago Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Wed, 26 Aug 2026 01:00:00 -0400 · 2 months ago ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
2026-07-08T09:15:13.000Z · 4 months ago Addex Therapeutics announces publication of new ADX71743 preclinical research
Thu, 25 Jun 2026 01:00:00 -0400 · 4 months ago Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mon, 22 Jun 2026 01:00:00 -0400 · 4 months ago Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Thu, 30 Apr 2026 01:00:00 -0400 · 6 months ago Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Wed, 29 Apr 2026 01:00:00 -0400 · 6 months ago Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
2026-04-23T09:46:20.000Z · 6 months ago Addex Therapeutics says spin-out company to complete NTX-253 study in Q2
Tue, 21 Apr 2026 01:00:00 -0400 · 6 months ago Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
2026-03-18T16:02:42.000Z · 7 months ago Addex Therapeutics Ltd – ADR trading halted, volatility trading pause
2026-02-03T10:40:43.000Z · 9 months ago Addex publishes negative allosteric modulators data in Molecular Psychiatry
2026-01-13T17:20:16.000Z · 10 months ago Addex Therapeutics Ltd – ADR trading halted, volatility trading pause
2026-01-07T10:10:23.000Z · 10 months ago Addex Therapeutics spin-out Neurosterix starts NTX-253 study
Wed, 07 Jan 2026 01:00:00 -0500 · 10 months ago Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Thu, 11 Dec 2025 01:00:00 -0500 · 11 months ago Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Thu, 04 Dec 2025 01:00:00 -0500 · 11 months ago Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Mon, 01 Dec 2025 01:00:00 -0500 · 11 months ago Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
2025-11-19T21:05:43.000Z · 11 months ago Addex Therapeutics files to sell $150M in ordinary shares ADXN
Tue, 30 Sep 2025 01:00:00 -0400 · 1 year ago Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Fri, 26 Sep 2025 01:00:00 -0400 · 1 year ago Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
Tue, 23 Sep 2025 01:00:00 -0400 · 1 year ago Addex Appoints Bank of New York Mellon as Depositary Bank
Mon, 30 Jun 2025 01:00:00 -0400 · 1 year ago Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
Mon, 30 Jun 2025 01:00:00 -0400 · 1 year ago Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Wed, 25 Jun 2025 01:00:00 -0400 · 1 year ago Addex Shareholders Approve All Resolutions at Annual General Meeting
2025-06-20T13:35:16.000Z · 1 year ago Addex Therapeutics Ltd – ADR trading halted, volatility trading pause
Jun 19, 2025, 1:00 AM EDT · 1 year ago Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Jun 18, 2025, 1:00 AM EDT · 1 year ago Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
2025-06-06T09:10:36.000Z · 1 year ago Addex reports anti-tussive activity of GABAB positive allosteric modulator
Jun 6, 2025, 1:00 AM EDT · 1 year ago Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
May 12, 2025, 1:00 AM EDT · 1 year ago Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Apr 30, 2025, 1:00 AM EDT · 1 year ago Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Apr 25, 2025, 1:00 AM EDT · 1 year ago Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
Nov 22, 2024, 1:00 AM EST · 1 year ago Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 11, 2024, 1:00 AM EST · 2 years ago Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
2024-09-30T09:30:24.000Z · 2 years ago Addex Therapeutics reports Q2 EPS CHF 0.08 vs. (CHF 0.04) last year
Sep 30, 2024, 1:00 AM EDT · 2 years ago Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Sep 19, 2024, 1:00 AM EDT · 2 years ago Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Sep 4, 2024, 1:00 AM EDT · 2 years ago Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-28T13:21:44.000Z · 2 years ago Clinical Collaboration Ignites Addex Therapeutics (ADXN) Stock Rally
Aug 27, 2024, 1:00 AM EDT · 2 years ago Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
2024-07-31T10:23:20.000Z · 2 years ago Addex Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Jul 22, 2024, 1:00 AM EDT · 2 years ago Addex's Partner Discontinues ADX71149 development in Epilepsy
Jul 15, 2024, 1:00 AM EDT · 2 years ago Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Jul 12, 2024, 1:00 AM EDT · 2 years ago Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Jun 6, 2024, 1:00 AM EDT · 2 years ago Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
May 31, 2024, 1:00 AM EDT · 2 years ago Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Apr 18, 2024, 1:00 AM EDT · 2 years ago Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update